February 27, 2026
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization to Rhapsido (remibrutinib, Novartis), an oral pill for treating […]
February 26, 2026
TOPLINE: Bimekizumab showed sustained improvements in International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS) over 48 weeks, with a […]
February 26, 2026
TOPLINE: Implementation of an emergency department (ED)-initiated walk-in dermatology pathway significantly reduced wait times for patients with atopic dermatitis (AD) and hidradenitis suppurativa (HS), and the […]
February 25, 2026
TOPLINE: In a cross-sectional analysis of approximately 11,000 clinical visits at Mexico-US border camps from 2020 to 2022, dermatologic conditions accounted for 6% of encounters and […]
February 24, 2026
Thousands of people with facial vitiligo could soon gain access to the first licensed repigmentation treatment on the NHS, after a policy reversal on cost-effectiveness grounds. […]
February 20, 2026
TOPLINE: An economic evaluation found that sunscreen costs varied substantially by unit price and clothing use, with annual expenses ranging from $39 to $1429, depending on […]
February 20, 2026
The FDA has approved topical difamilast for treating mild-to-moderate atopic dermatitis (AD) in adults and children aged 2 years or older, according to a press release […]
February 19, 2026
TOPLINE: In a multicentre real-world study, treatment with amivantamab was associated with diverse dermatologic adverse events in patients with non-small cell lung cancer (NSCLC), with 65.9% […]
February 19, 2026
TOPLINE: Dupilumab, approved in 2025 by the US FDA to treat chronic spontaneous urticaria (CSU), significantly reduced symptoms in patients with antihistamine (AH)-resistant CSU in a […]